InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
2
T+90 hit rate
9%
T+90 mean return
-14.9%
Across 11 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Goddard Glenn, Chief Financial Officer. Director active across 1 company, notably Intellia Therapeutics, Inc.. In total, 13 reports have been logged. Split: 0 buy · 2 sells. Total volume traded: €230k. Activity tracked since 5 August 2021. The latest transaction was disclosed on 1 March 2024 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations13 total
28,628 shares0Common StockSEC:0000950170-24-025901:0
5,365 shares@ US$29.4612.7% of flowCommon StockSEC:0000950170-24-002511:0
3,062 sharesCommon StockSEC:0000950170-24-001173:0
27,484 shares0Common StockSEC:0001209191-23-015776:0
2,427 shares@ US$37.217.5% of flowCommon StockSEC:0001209191-23-002414:0
3,062 sharesCommon StockSEC:0001209191-23-001490:0
3,062 sharesCommon StockSEC:0001209191-22-015917:0
3,482 shares@ US$14.580.0022% mcap4.7% of flowCommon StockSEC:0001209191-21-055347:0
3,482 shares@ US$14.583.8% of flowCommon StockSEC:0001209191-21-055347
5,200 shares@ US$19.277.5% of flowCommon StockSEC:0001209191-21-054315
5,200 shares@ US$19.270.0044% mcap9.4% of flowCommon StockSEC:0001209191-21-054315:0
20,000 shares@ US$19.270.017% mcap35.9% of flowCommon StockSEC:0001209191-21-050225:0
20,000 shares@ US$19.2728.6% of flowCommon StockSEC:0001209191-21-050225
13 of 13 declarations
About Goddard Glenn
Glenn Goddard is Executive Vice President and Chief Financial Officer at Intellia Therapeutics, Inc. He is responsible for the financial management of the company, including financial planning, performance analysis, and regulatory compliance. His expertise in finance is crucial to support growth and optimize financial results. Glenn also plays a key role in investment strategy and risk management.
